Show simple item record

dc.contributor.authorColeman, R
dc.contributor.authorBrown, J
dc.contributor.authorRathbone, E
dc.contributor.authorFlanagan, L
dc.contributor.authorReid, A
dc.contributor.authorKendall, J
dc.contributor.authorHowell, Sacha J
dc.contributor.authorTwelves, C
dc.contributor.authorPalmieri, C
dc.contributor.authorAnand, A
dc.contributor.authorMacPherson, I
dc.contributor.authorBrown, S
dc.date.accessioned2020-02-27T16:55:22Z
dc.date.available2020-02-27T16:55:22Z
dc.date.issued2020en
dc.identifier.citationColeman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, et al. CApecitabine plus Radium-223 (Xofigo) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials. 2020;21(1):89.en
dc.identifier.pmid31941523en
dc.identifier.doi10.1186/s13063-019-3643-6en
dc.identifier.urihttp://hdl.handle.net/10541/622751
dc.description.abstractBACKGROUND: A substantial proportion of breast cancer patients develop metastatic disease, with over 450,000 deaths globally per year. Bone is the most common first site of metastatic disease accounting for 40% of all first recurrence and 70% of patients with advanced disease develop skeletal involvement. Treatment of bone metastases currently focusses on symptom relief and prevention and treatment of skeletal complications. However, there remains a need for further treatment options for patients with bone metastases. Combining systemic therapy with a bone-targeted agent, such as radium-223, may provide an effective treatment with minimal additional side effects. METHODS/DESIGN: CARBON is a UK-based, open-label, multi-centre study which comprises an initial safety phase to establish the feasibility and safety of combining radium-223 given on a 6-weekly schedule in combination with orally administered capecitabine followed by a randomised extension phase to further characterise the safety profile and provide preliminary estimation of efficacy. DISCUSSION: The CARBON study is important as the results will be the first to assess radium-223 with chemotherapy in advanced breast cancer. If the results find acceptable rates of toxicity with a decrease in bone turnover markers, further work will be necessary in a phase II/III setting to assess the efficacy and clinical benefit. TRIAL REGISTRATION: ISRCTN, ISRCTN92755158, Registered on 17 February 2016.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1186/s13063-019-3643-6en
dc.titleCApecitabine plus Radium-223 (Xofigo) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trialen
dc.typeArticleen
dc.contributor.departmentThe University of Sheffield, Sheffield, UKen
dc.identifier.journalTrialsen
dc.description.noteen]
refterms.dateFOA2020-03-03T14:05:31Z


Files in this item

Thumbnail
Name:
31941523.pdf
Size:
1.423Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record